Skip to main content
Erschienen in: Irish Journal of Medical Science (1971 -) 2/2014

01.06.2014 | Original Article

Familial breast cancer genetic testing in the West of Ireland

verfasst von: T. P. McVeigh, R. Irwin, N. Cody, N. Miller, T. McDevitt, K. J. Sweeney, A. Green, M. J. Kerin

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Aims

The majority of hereditary breast and ovarian cancers are associated with highly penetrant mutations in two genes: BRCA 1 and 2. Our aim was to investigate the prevalence and types of BRCA mutations in patients from the West of Ireland.

Methods

A retrospective cohort study was undertaken that included all patients from the counties, Mayo, Sligo, Galway, Roscommon, and Clare, who were referred to the National Centre for Medical Genetics (NCMG) for testing for mutations in BRCA 1 or 2 between 2000 and 2010. Data including age, symptoms, family history, Manchester score, and test results were recorded and analysed using SPSS.

Results

The NCMG received 380 referrals from the Western seaboard, including 148 for diagnostic testing and 232 for predictive evaluation. Sixty-five patients did not attend for assessment. Two hundred and fifty-six patients fulfilled criteria for genetic counselling, which was accepted by 184, of whom 127 proceeded to testing. Predictive tests were more often declined than diagnostic [41 (46 %) vs. 16 (17 %)]. Ten mutations in BRCA 1 were identified in 20 patients (15 families), including Exon 1–23del (3 families); Exon 14–20del (2 families) and E143X (2 families). Six mutations in BRCA 2 were identified in 15 patients (12 families) including 8525delC (n = 2 families) and 8205-1G>C (n = 3 families). Patients with positive results had significantly higher Manchester scores than those with negative tests [median 25.5 (12–48) vs. 20 (8–37), p = 0.042, Mann–Whitney U test].

Conclusion

To identify patients with highly penetrant variants, referrals should be made with strict adherence to guidelines. Counselling should be individualised to counteract intrinsic psychological barriers to testing.
Literatur
2.
Zurück zum Zitat Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA 1 and BRCA 2 mutations in a population-based series of breast cancer cases. Br J Cancer 83(10):1301–1308PubMedCentralCrossRef Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA 1 and BRCA 2 mutations in a population-based series of breast cancer cases. Br J Cancer 83(10):1301–1308PubMedCentralCrossRef
3.
Zurück zum Zitat Antoniou AC, Pharoah PDP, McMullan G et al (2002) A comprehensive model for familial breast cancer incorporating BRCA 1, BRCA 2 and other genes. Br J Cancer 86(1):76–83PubMedCentralPubMedCrossRef Antoniou AC, Pharoah PDP, McMullan G et al (2002) A comprehensive model for familial breast cancer incorporating BRCA 1, BRCA 2 and other genes. Br J Cancer 86(1):76–83PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat O’Donovan PJ, Livingston DM (2010) BRCA 1 and BRCA 2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 31(6):961–967PubMedCrossRef O’Donovan PJ, Livingston DM (2010) BRCA 1 and BRCA 2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 31(6):961–967PubMedCrossRef
5.
Zurück zum Zitat Janavičius R (2010) Founder BRCA 1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J 1(3):397–412PubMedCentralPubMedCrossRef Janavičius R (2010) Founder BRCA 1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J 1(3):397–412PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Mann GJ, Thorne H, Balleine RL et al (2006) Analysis of cancer risk and BRCA 1 and BRCA 2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 8(1):R12PubMedCentralPubMedCrossRef Mann GJ, Thorne H, Balleine RL et al (2006) Analysis of cancer risk and BRCA 1 and BRCA 2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 8(1):R12PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Risch HA, McLaughlin JR, Cole DEC et al (2006) Population BRCA 1 and BRCA 2 mutation frequencies and cancer penetrance: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98(23):1694–1706PubMedCrossRef Risch HA, McLaughlin JR, Cole DEC et al (2006) Population BRCA 1 and BRCA 2 mutation frequencies and cancer penetrance: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98(23):1694–1706PubMedCrossRef
8.
Zurück zum Zitat Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA 1-mutation carriers. Breast cancer linkage consortium. Lancet 343(8899):692–695PubMedCrossRef Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA 1-mutation carriers. Breast cancer linkage consortium. Lancet 343(8899):692–695PubMedCrossRef
9.
Zurück zum Zitat Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA 1 and BRCA 2 genes in breast cancer families. Am J Hum Genet 62(3):676–689PubMedCentralPubMedCrossRef Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA 1 and BRCA 2 genes in breast cancer families. Am J Hum Genet 62(3):676–689PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Antoniou A, Pharoah PDP, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA 1 or BRCA 2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130PubMedCentralPubMedCrossRef Antoniou A, Pharoah PDP, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA 1 or BRCA 2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Easton DF, Matthews FE, Ford D et al (1996) Cancer mortality in relatives of women with ovarian cancer: the OPCS study. Int J Cancer 65(3):284–294PubMedCrossRef Easton DF, Matthews FE, Ford D et al (1996) Cancer mortality in relatives of women with ovarian cancer: the OPCS study. Int J Cancer 65(3):284–294PubMedCrossRef
12.
Zurück zum Zitat Peto J, Easton DF, Matthews FE et al (1996) Cancer mortality in relatives of women with breast cancer: the OPCS study. Int J Cancer 65(3):275–283PubMedCrossRef Peto J, Easton DF, Matthews FE et al (1996) Cancer mortality in relatives of women with breast cancer: the OPCS study. Int J Cancer 65(3):275–283PubMedCrossRef
13.
Zurück zum Zitat Antoniou A, Pharoah PDP, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA 1 or BRCA 2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130PubMedCentralPubMedCrossRef Antoniou A, Pharoah PDP, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA 1 or BRCA 2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Friedenson B (2005) BRCA 1 and BRCA 2 pathways and the risk of cancers other than breast or ovarian. Med Gen Med 7(2):60 Friedenson B (2005) BRCA 1 and BRCA 2 pathways and the risk of cancers other than breast or ovarian. Med Gen Med 7(2):60
15.
Zurück zum Zitat McEvoy B, Richards M, Forster P et al (2004) The longue dureé of genetic ancestry: multiple genetic marker systems and celtic origins on the Atlantic facade of Europe. Am J Hum Genet 75(4):693–702PubMedCentralPubMedCrossRef McEvoy B, Richards M, Forster P et al (2004) The longue dureé of genetic ancestry: multiple genetic marker systems and celtic origins on the Atlantic facade of Europe. Am J Hum Genet 75(4):693–702PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Wilson JF, Weiss DA, Richards M et al (2001) Genetic evidence for different male and female roles during cultural transitions in the British Isles. Proc Natl Acad Sci USA 98(9):5078–5083PubMedCentralPubMedCrossRef Wilson JF, Weiss DA, Richards M et al (2001) Genetic evidence for different male and female roles during cultural transitions in the British Isles. Proc Natl Acad Sci USA 98(9):5078–5083PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Hill EW, Jobling MA, Bradley DG (2000) Y-chromosome variation and Irish origins. Nature 404(6776):351–352PubMedCrossRef Hill EW, Jobling MA, Bradley DG (2000) Y-chromosome variation and Irish origins. Nature 404(6776):351–352PubMedCrossRef
18.
Zurück zum Zitat O’Dushlaine CT, Dolan C, Weale ME et al (2008) An assessment of the Irish population for large-scale genetic mapping studies involving epilepsy and other complex diseases. Eur J Hum Genet 16(2):176–183PubMedCrossRef O’Dushlaine CT, Dolan C, Weale ME et al (2008) An assessment of the Irish population for large-scale genetic mapping studies involving epilepsy and other complex diseases. Eur J Hum Genet 16(2):176–183PubMedCrossRef
19.
Zurück zum Zitat Abeliovich D, Kaduri L, Lerer I et al (1997) The founder mutations 185delAG and 5382insC in BRCA 1 and 6174delT in BRCA 2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60(3):505–514PubMedCentralPubMed Abeliovich D, Kaduri L, Lerer I et al (1997) The founder mutations 185delAG and 5382insC in BRCA 1 and 6174delT in BRCA 2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60(3):505–514PubMedCentralPubMed
20.
Zurück zum Zitat Oddoux C, Struewing JP, Clayton CM et al (1996) The carrier frequency of the BRCA 2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14(2):188–190PubMedCrossRef Oddoux C, Struewing JP, Clayton CM et al (1996) The carrier frequency of the BRCA 2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14(2):188–190PubMedCrossRef
21.
Zurück zum Zitat Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA 1 and BRCA 2 among Ashkenazi Jews. N Engl J Med 336(20):1401–1408PubMedCrossRef Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA 1 and BRCA 2 among Ashkenazi Jews. N Engl J Med 336(20):1401–1408PubMedCrossRef
22.
Zurück zum Zitat WHO (2004) The molecular genetic epidemiology of cystic fibrosis: report of a joint meeting of World Health Organisation; European Cystic Fibrosis Thematic Network; International Cystic Fibrosis (Mucoviscidosis) Association; European Cystic Fibrosis Society WHO (2004) The molecular genetic epidemiology of cystic fibrosis: report of a joint meeting of World Health Organisation; European Cystic Fibrosis Thematic Network; International Cystic Fibrosis (Mucoviscidosis) Association; European Cystic Fibrosis Society
23.
Zurück zum Zitat Brédart A, Autier P, Audisio RA et al (1998) Psycho-social aspects of breast cancer susceptibility testing: a literature review. Eur J Cancer Care 7(3):174–180CrossRef Brédart A, Autier P, Audisio RA et al (1998) Psycho-social aspects of breast cancer susceptibility testing: a literature review. Eur J Cancer Care 7(3):174–180CrossRef
24.
Zurück zum Zitat Lynch HT, Snyder C, Lynch JF et al (2006) Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families. Cancer Genet Cytogenet 165(2):91–97PubMedCrossRef Lynch HT, Snyder C, Lynch JF et al (2006) Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families. Cancer Genet Cytogenet 165(2):91–97PubMedCrossRef
25.
Zurück zum Zitat Douglas HA, Hamilton RJ, Grubs RE (2009) The effect of BRCA gene testing on family relationships: a thematic analysis of qualitative interviews. J Genet Couns 18(5):418–435PubMedCrossRef Douglas HA, Hamilton RJ, Grubs RE (2009) The effect of BRCA gene testing on family relationships: a thematic analysis of qualitative interviews. J Genet Couns 18(5):418–435PubMedCrossRef
26.
Zurück zum Zitat Kwon JS, Gutierrez-Barrera AM, Young D et al (2010) Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 28(27):4214–4220PubMedCrossRef Kwon JS, Gutierrez-Barrera AM, Young D et al (2010) Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 28(27):4214–4220PubMedCrossRef
27.
Zurück zum Zitat Balmaña J, Díez O, Rubio IT et al (2011) BRCA in breast cancer: ESMO clinical practice guidelines. Ann Oncol 22(SUPPL. 6):vi31–vi34PubMed Balmaña J, Díez O, Rubio IT et al (2011) BRCA in breast cancer: ESMO clinical practice guidelines. Ann Oncol 22(SUPPL. 6):vi31–vi34PubMed
28.
Zurück zum Zitat Robson ME, Storm CD, Weitzel J et al (2010) American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 28(5):893–901PubMedCrossRef Robson ME, Storm CD, Weitzel J et al (2010) American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 28(5):893–901PubMedCrossRef
29.
Zurück zum Zitat Evans DGR, Eccles DM, Rahman N et al (2004) A new scoring system for the chances of identifying a BRCA 1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41(6):474–480PubMedCentralPubMedCrossRef Evans DGR, Eccles DM, Rahman N et al (2004) A new scoring system for the chances of identifying a BRCA 1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41(6):474–480PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat NICE, NICE guideline CG041 (2006) Familial breast cancer. The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. NICE, London NICE, NICE guideline CG041 (2006) Familial breast cancer. The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. NICE, London
31.
Zurück zum Zitat McDevitt T, Higgins M, Crowley A et al (2010) Spectrum and incidence of BRCA 1 and BRCA 2 mutations in the Republic of Ireland—an audit (abstract). Ulster Med J 79(1):33–42 McDevitt T, Higgins M, Crowley A et al (2010) Spectrum and incidence of BRCA 1 and BRCA 2 mutations in the Republic of Ireland—an audit (abstract). Ulster Med J 79(1):33–42
32.
Zurück zum Zitat Altshuler DM, Gibbs RA, Peltonen L et al (2010) Integrating common and rare genetic variation in diverse human populations. Nature 467(7311):52–58PubMedCrossRef Altshuler DM, Gibbs RA, Peltonen L et al (2010) Integrating common and rare genetic variation in diverse human populations. Nature 467(7311):52–58PubMedCrossRef
34.
Zurück zum Zitat Ticha I, Kleibl Z, Stribrna J et al (2010) Screening for genomic rearrangements in BRCA 1 and BRCA 2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA 1 gene. Breast Cancer Res Treat 124(2):337–347PubMedCrossRef Ticha I, Kleibl Z, Stribrna J et al (2010) Screening for genomic rearrangements in BRCA 1 and BRCA 2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA 1 gene. Breast Cancer Res Treat 124(2):337–347PubMedCrossRef
35.
Zurück zum Zitat Palma MD, Domchek SM, Stopfer J et al (2008) The relative contribution of point mutations and genomic rearrangements in BRCA 1 and BRCA 2 in high-risk breast cancer families. Cancer Res 68(17):7006–7014PubMedCentralPubMedCrossRef Palma MD, Domchek SM, Stopfer J et al (2008) The relative contribution of point mutations and genomic rearrangements in BRCA 1 and BRCA 2 in high-risk breast cancer families. Cancer Res 68(17):7006–7014PubMedCentralPubMedCrossRef
37.
Zurück zum Zitat Foster C, Evans DGR, Eeles R et al (2004) Non-uptake of predictive genetic testing for BRCA 1/2 among relatives of known carriers: attributes, cancer worry, and barriers to testing in a multicenter clinical cohort. Genet Testing 8(1):23–29CrossRef Foster C, Evans DGR, Eeles R et al (2004) Non-uptake of predictive genetic testing for BRCA 1/2 among relatives of known carriers: attributes, cancer worry, and barriers to testing in a multicenter clinical cohort. Genet Testing 8(1):23–29CrossRef
38.
Zurück zum Zitat Meiser B (2005) Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psychooncology 14(12):1060–1074PubMedCrossRef Meiser B (2005) Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psychooncology 14(12):1060–1074PubMedCrossRef
39.
Zurück zum Zitat Carroll JC, Heisey RE, Warner E et al (1999) Hereditary breast cancer: psychosocial issues and family physicians’ role. Can Fam Physician 45:126–132PubMedCentralPubMed Carroll JC, Heisey RE, Warner E et al (1999) Hereditary breast cancer: psychosocial issues and family physicians’ role. Can Fam Physician 45:126–132PubMedCentralPubMed
40.
Zurück zum Zitat Thompson HS, Valdimarsdottir HB, Duteau-Buck C et al (2002) Psychosocial predictors of BRCA counselling and testing decisions among urban African-American women. Cancer Epidemiol Biomark Prev 11(12):1579–1585 Thompson HS, Valdimarsdottir HB, Duteau-Buck C et al (2002) Psychosocial predictors of BRCA counselling and testing decisions among urban African-American women. Cancer Epidemiol Biomark Prev 11(12):1579–1585
41.
Zurück zum Zitat van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ et al (2007) A prospective study of the impact of genetic susceptibility testing for BRCA 1/2 or HNPCC on family relationships. Psychooncology 16(4):320–328PubMedCrossRef van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ et al (2007) A prospective study of the impact of genetic susceptibility testing for BRCA 1/2 or HNPCC on family relationships. Psychooncology 16(4):320–328PubMedCrossRef
42.
Zurück zum Zitat Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25(43):5898–5905PubMedCrossRef Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25(43):5898–5905PubMedCrossRef
43.
Zurück zum Zitat McInerney NM, Miller N, Rowan A et al (2010) Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort. Breast Cancer Res Treat 121(1):203–210PubMedCrossRef McInerney NM, Miller N, Rowan A et al (2010) Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort. Breast Cancer Res Treat 121(1):203–210PubMedCrossRef
44.
Zurück zum Zitat Smith P, McGuffog L, Easton DF et al (2006) A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosom Cancer 45(7):646–655PubMedCentralPubMedCrossRef Smith P, McGuffog L, Easton DF et al (2006) A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosom Cancer 45(7):646–655PubMedCentralPubMedCrossRef
45.
Zurück zum Zitat Pharoah PDP, Antoniou A, Bobrow M et al (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31(1):33–36PubMedCrossRef Pharoah PDP, Antoniou A, Bobrow M et al (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31(1):33–36PubMedCrossRef
Metadaten
Titel
Familial breast cancer genetic testing in the West of Ireland
verfasst von
T. P. McVeigh
R. Irwin
N. Cody
N. Miller
T. McDevitt
K. J. Sweeney
A. Green
M. J. Kerin
Publikationsdatum
01.06.2014
Verlag
Springer London
Erschienen in
Irish Journal of Medical Science (1971 -) / Ausgabe 2/2014
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-013-0990-2

Weitere Artikel der Ausgabe 2/2014

Irish Journal of Medical Science (1971 -) 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.